Viridian Therapeutics, Inc. VRDN
At closeNov 3, 2026, 4:30 PM EST
After hours · Nov 3, 4:30 PM ET
- YTD
- -19.18%
- 1 year
- +8.64%
- Market cap
- 2.85B
- Revenue (ttm)
- 71.13M
- EPS (ttm)
- -3.39
- Shares out
- 113.29M
- Forward P/E
- -9.28
- YTD return
- -19.18%
- 1-year return
- +8.64%
- Volume
- 4.06M
- Avg volume
- 1.84M
- Open
- 25.61
- Previous close
- 25.30
- Day's range
- 24.52 – 26.21
- 52-week range
- 13.18 – 34.29
- Beta
- 1.07
- Analysts
- Strong Buy
- Price target
- 36.20 (+43.9%)
- Earnings date
- Nov 4, 2026
2Y +2.26 (+9.89%)
Key statistics
- Enterprise value
- 2.23B
- PEG ratio
- 0.00
- Price / sales
- 40.06
- Price / book
- 5.05
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 278.70%
- Free cash flow
- -275.50M
- Total cash
- 981.53M
- Total debt
- 244.73M
- Return on equity
- -65.74%
- Short % of float
- 16.47%
- 50-day average
- 21.68
- 200-day average
- 21.72
Analyst view
Consensus: strong buy
- Target (low)
- 22.00
- Target (mean)
- 36.20
- Target (high)
- 50.00
- Strong buy3
- Buy14
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -1.02.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -1.02 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -1.03 | -1.05 | -0.02 | -1.94% |
| May 5, 2026 | Mar 31, 2026 | -1.06 | -0.90 | +0.16 | +15.09% |
| Feb 26, 2026 | Dec 31, 2025 | -0.90 | -1.08 | -0.18 | -20.00% |
| Nov 5, 2025 | Sep 30, 2025 | -0.82 | -0.34 | +0.48 | +58.54% |
| Aug 6, 2025 | Jun 30, 2025 | -1.00 | -1.00 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 22, 2026 | RBC Capital | main | Outperform | Outperform |
| Aug 7, 2026 | RBC Capital | main | Outperform | Outperform |
| Aug 7, 2026 | Truist Securities | main | Buy | Buy |
| Jun 30, 2026 | RBC Capital | main | Outperform | Outperform |
| Jun 30, 2026 | Truist Securities | main | Buy | Buy |
| Jun 30, 2026 | Wedbush | main | Outperform | Outperform |
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- viridiantherapeutics.com
News
Viridian Intersects 15m of 1.1% CuEq in 1.5km Step-Out Drilling at Kraken Main 
Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026 
Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy 
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Now Rated “Moderate Buy” by Sell-Side Analysts 
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $38 
Viridian Therapeutics: Two Products, One Commercial Buildout 
Viridian Intersects Over 50 Metres of Mineralization from Surface at Kraken Main 
27,472 Shares in Viridian Therapeutics, Inc. $VRDN Acquired by Jupiter Topco LLC 
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying 
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Your note
Sign in to keep a note on VRDN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEETHAM THOMAS W | Chief Operating Officer | Conversion of Exercise of derivative security | Mar 2, 2026 | 13,361 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 10, 2026 | 0 |
| HARMON SETH | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 2, 2026 | 7,850 |
| MAHONEY STEPHEN F | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 2, 2026 | 33,349 |
| TOUSIGNANT JENNIFER | Officer | Conversion of Exercise of derivative security | Aug 18, 2026 | 0 |
| TRIPURANENI RADHIKA | Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 40,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.66% | 16,604,740 | 417.61M | Jun 29, 2026 |
| Blackrock Inc. | 7.55% | 8,551,488 | 215.07M | Jun 29, 2026 |
| Bellevue Group AG | 5.94% | 6,731,909 | 169.31M | Jun 29, 2026 |
| Paradigm Biocapital Advisors LP | 5.93% | 6,723,788 | 169.10M | Jun 29, 2026 |
| Kynam Capital Management, LP | 5.70% | 6,453,877 | 162.32M | Jun 29, 2026 |
| State Street Corporation | 5.41% | 6,124,976 | 154.04M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.95% | 3,336,970 | 83.92M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.29% | 2,590,081 | 65.14M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.20% | 2,495,461 | 62.76M | Sep 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 1.57% | 1,782,464 | 44.83M | Aug 30, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.32% | 1,500,000 | 37.72M | Aug 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1.28% | 1,447,742 | 36.41M | Jun 29, 2026 |